Skip to main content
×
×
Home

Vortioxetine for depression: the evidence for its current use in the UK: COMMENTARY ON… COCHRANE CORNER

  • Riccardo De Giorgi (a1)
Summary

The pharmacological treatment of depression is often hampered by side-effects and unsatisfactory response to treatment. Vortioxetine is one of the newest antidepressants on the market, purportedly with a different mechanism of action compared with other antidepressants. This month's Cochrane Corner review examines the evidence available for the use of vortioxetine as a first-line treatment for depression in adults. This commentary puts the Cochrane review's findings into their clinical context and revises them in view of earlier and later studies.

DECLARATION OF INTEREST

None.

Copyright
Corresponding author
Correspondence Dr Riccardo De Giorgi, Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK. Email: riccardo.degiorgi@bnc.ox.ac.uk
Footnotes
Hide All

See this issue

Footnotes
References
Hide All
Cipriani, A, Furukawa, TA, Salanti, G, et al. (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 391: 1357–66.
European Medicines Agency (2014) Brintellix: Vortioxetine. Procedure No. EMEA/H/C/002717 (EPAR, Public Assessment Report). EMA (https://www.ema.europa.eu/documents/assessment-report/brintellix-epar-public-assessment-report_en.pdf).
Kennedy, SH, Lam, RW, McIntyre, RS, et al. (2016) Clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Canadian Journal of Psychiatry, 61: 540–60.
Koesters, M, Ostuzzi, G, Guaiana, G, et al. (2017) Vortioxetine for depression in adults. Cochrane Database of Systematic Reviews, 7: CD011520 (doi: 10.1002/14651858.CD011520.pub2).
Linde, K, Kriston, L, Rücker, G, et al. (2015) Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Annals of Family Medicine, 13: 6979.
Lundbeck (2016) PrTRINTELLIX®: Vortioxetine (as Vortioxetine Hydrobromide) 5 mg, 10 mg, 15 mg, and 20 mg Tablets (Product Monograph). Lundbeck (https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Trintellix.pdf).
McIntyre, RS, Filteau, MJ, Martin, L, et al. (2014) Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders, 156: 17.
McIntyre, RS (2017) The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatric Disease and Treatment, 13: 2913–9.
Montgomery, SA, Moller, HJ (2009) Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? International Clinical Psychopharmacology, 24: 111–8.
Montgomery, SA, Nielsen, RZ, Poulsen, LH, et al. (2014) A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Human Psychopharmacology, 29: 470–82.
National Institute for Health and Care Excellence (2015) Vortioxetine for Treating Major Depressive Episodes (Technology Appraisal Guidance TA367). NICE (https://www.nice.org.uk/guidance/ta367).
Saltiel, PF, Silvershein, DI (2015) Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatric Disease and Treatment, 11: 875–88.
Sanchez, C, Asin, KE, Artigas, F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology and Therapeutics, 145: 4357.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Advances
  • ISSN: 2056-4678
  • EISSN: 2056-4686
  • URL: /core/journals/bjpsych-advances
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Vortioxetine for depression: the evidence for its current use in the UK: COMMENTARY ON… COCHRANE CORNER

  • Riccardo De Giorgi (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *